Humana (HUM) Stock Forecast & Price Target

Humana's strong outlook is supported by significant improvements in the Group Medicare Advantage (MA) margin, which increased by 500 basis points, indicating robust contract re-negotiation success. The company anticipates continued revenue growth across its Specialty, Direct-to-Consumer, Direct-to-Employer, and Home Delivery segments, coupled with expected enhancements in margins driven by lower marketing costs and better risk adjustments. Additionally, CenterWell demonstrated a solid revenue increase of 16% primarily due to pharmacy performance, further underscoring Humana’s growth potential despite the challenges of rising operating costs.

Humana faces multiple challenges that contribute to a negative outlook, including increased competition in Medicare Advantage (MA) and inadequate reimbursement rates, which may adversely affect its financial stability. The company is grappling with a significant estimated $3.5 billion headwind due to declining MA Star ratings, which could result in a approximately $22 EPS drag for 2026. Additionally, projected declines in net investment income and slower growth in healthcare services further exacerbate the financial pressures, suggesting a difficult path ahead for the company's profitability.